Aspetti emergenti

In questa sezione sono presenti una serie di aggiornamenti riguardanti gli aspetti emergenti sugli interferenti endocrini quali aggiornamenti su aspetti nuovi o sinora trascurati della valutazione del rischio degli Interferenti endocrini; approcci innovativi, correlazioni con patologie, nuove sostanze identificate come interferenti endocrini (IE).

• Catone T, Leonello Attias L, Mantovani A. Interferenti endocrini in cosmetici e capi d'abbigliamento. Notiziario dell'Istituto Superiore di Sanità.  2021;34(3):7-11
• Vitamin A joins Endocrine Disruption. OpenAccess Government, June 2020
• Contaminants and infections: a link to explore. OpenAccess Government, April 2020
• Kucheryavenko O, Lurman G, Lehmann A, Braz J, Niemann L, Chahoud I, Mantovani A, Håkansson H, SchneiderS , Strauss V, Coder PS, Freyberger A, O’Connor JC, Rauch M, Renko K, Solano MLM, Andersson N, Blanck O, Ritz V & Solecki R. Report from the BfR expert hearing on practicability of hormonal measurements: recommendations for experimental design of toxicological studies with integrated hormonal end points. Archives of Toxicology. 2019; 93(4):1157-1167
• Climate change: Modifying our views on environmental risks. OpenAccess Government, September 2019
• Thyroid Disruption: the report of the EU Workshop (March 2017)
• Bopp S, Nepelska M, Halder M, Munn S. Expert survey on identification of gaps in available test methods for evaluation of endocrine disruptors. JRC Technical Report, EUR 28592 EN
• Mantovani A. Why research on Endocrine Disrupting Chemicals is still worthwhile. Annali dell'Istituto Superiore di Sanità. 2017; 53(1):1-2
• Heindel JJ, Blumberg B, Cave M, Machtinger R, Mantovani A, Mendez MA, Nadal A, Palanza P, Panzica G, Sargis R, Vandenberg LN, Vom Saal F. Metabolism Disrupting Chemicals and Metabolic Disorders. Reproductive Toxicology. 2017; 68:3-33